PRESS RELEASES

Savient Pharmaceuticals, Inc. (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investor Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The statements contained in this website contain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts included in the website are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding our view of the refractory chronic gout (RCG) market size based on the completion of our recent comprehensive market research study, the status of our KRYSTEXXA® marketing efforts in the United States and additional plans related thereto, market demand and reimbursement for KRYSTEXXA in the United States, our preparations for and the timing of our market expansion plans, including regulatory submissions and potential marketing approvals for KRYSTEXXA in jurisdictions outside of the United States, including the European Union, the clinical benefits of KRYSTEXXA and our investigation of the expansion of the clinical utility of KRYSTEXXA, the likelihood of our being able to identify an appropriate strategic licensing or co-promotion transaction in certain territories, our work with secondary supply sources, and related matters are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the actual market size for KRYSTEXXA, our ability to commercialize and gain market acceptance for KRYSTEXXA, market demand for KRYSTEXXA and market acceptance of reimbursement risks with third-party payers, risks associated with stringent government regulation of the biopharmaceutical industry, and in particular the approval of regulatory submissions and marketing approvals, the efficacy of KRYSTEXXA and our ability to expand its clinical utility, whether we are able to identify an appropriate strategic licensing or co-promotion transaction, our reliance on secondary supply sources to manufacture, market and distribute our products; and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this website to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.